Another look at the human papillomavirus vaccine experience in Canada

American Journal of Public Health

Volumn 101, Issue 10, 2011, Pages 1850-1857

  Mah, Catherine L ^a   Deber, Raisa B ^a   Guttmann, Astrid ^b   McGeer, Allison ^c   Krahn, Murray ^d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; WART VIRUS VACCINE;

ARTICLE; CANADA; HEALTH CARE POLICY; HUMAN; MANAGEMENT; MANDATORY PROGRAM; ORGANIZATION AND MANAGEMENT; PAPILLOMAVIRUS INFECTION; POLITICS; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; UNITED STATES; WOMEN'S HEALTH;

CANADA; CANCER VACCINES; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; MANDATORY PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLICY MAKING; POLITICS; PUBLIC HEALTH; UNITED STATES; WOMEN'S HEALTH;

EID: 80052972540     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2011.300205     Document Type: Article

References (76)

1. Healthy People 2010: Understanding and Improving Health. Washington, DC: US Department of Health and Human Services; 2000. Also available at: http://web.health.gov/healthypeople/document. Accessed May 12, 2011.
2. Gauri V, Khaleghian P. Immunization in Developing Countries: Its Political and Organizational Determinants. Washington, DC: World Bank; 2002. World Bank Policy Research Working Paper 2769.
3. Siegal G, Siegal N, Bonnie RJ. An account of collective actions in public health. Am J Public Health. 2009;99(9): 1583-1587.
4. National Advisory Committee on Immunization. Statement on human papillomavirus vaccine. Canada Communicable Disease Report. 2007;33(ACS-2):1-32.
5. Dawar M, Dobson S, Deeks S. Literature Review on HPV 6, 11, 16 and 18: Disease and Characteristics. Review commissioned by the Public Health Agency of Canada. Ottawa, Canada: Public Health Agency of Canada; 2007. Available at: http://www.atlantique.phac.gc.ca/naci-ccni/pdf/lr-sl-2-e.pdf. Accessed July 12, 2010.
6. US Centers for Disease Control and Prevention. HPV-Associated Cervical Cancer Rates by Race and Ethnicity. Atlanta, GA: Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion. Available at: http://www.cdc.gov/cancer/hpv/statistics/cervical.htm. Accessed April 5, 2010.
7. Health Canada. Notice of Decision for Gardasil, October 23, 2006. Ottawa, Canada: Health Canada; 2006.
8. US Food and Drug Administration. FDA licenses new vaccine for prevention of cervical cancer and other diseases caused by human papillomavirus: Rapid approval marks major advancement in public health [media release]. Silver Spring, MD: US Department of Health and Human Services; June 8, 2006. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108666. htm. Accessed April 11, 2010.
9. Merck. Gardasil approved by Health Canada for males to prevent genital warts [media release]. Kirkland, Canada: Merck; February 23, 2010. Available at: http://www.merckfrosst.ca/assets/en/pdf/press/product-info/gardasil/press- releases/Gardasil-Male-News-Release-EN.pdf. Accessed April 1, 2010.
10. US Food and Drug Administration. FDA approves new indication for Gardasil to prevent genital warts in men and boys [media release]. Silver Spring, MD: US Department of Health and Human Services; October 16, 2009. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108666.htm. Accessed April 5, 2010.
11. GlaxoSmithKline. Health Canada approves Cervarix, new GSK cervical cancer vaccine [media release]. Mississauga, Canada: GlaxoSmithKline; February 9, 2010. Available at: http://www.gsk.ca/english/docs-pdf/FINAL-Press-Release- Cervarix-EN.pdf. Accessed April 5, 2010.
12. US Food and Drug Administration. FDA approves new vaccine for prevention of cervical cancer [media release]. Silver Spring, MD: US Department of Health and Human Services; October 16, 2009. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm187048.htm. Accessed April 11, 2010.
13. Erickson LJ, DeWals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine. 2005; 23(19):2470-2476.
14. Gostin LO. Public Health Law: Power, Duty, Restraint. Berkeley, CA: University of California Press; 2000.
15. Gostin LO, DeAngelis CD. Mandatory HPV vaccination: public health versus private wealth. JAMA. 2007;297(17): 1921-1923. (Pubitemid 46707847)
16. Balog JE. The moral justification for a compulsory human papillomavirus vaccination program. Am J Public Health. 2009;99(4):616-622.
17. Charo RA. Politics, parents, and prophylaxis-mandatory HPV vaccination in the United States. N Engl J Med. 2007; 356(19):1905-1908. (Pubitemid 46740299)
18. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med. 2006;355(23):2389-2391. (Pubitemid 44903743)
19. Nelson R. Politics and power plays behind the HPV vaccine: an effective vaccine is mired in controversy by mandates. Am J Nurs. 2007;107(8):23-24.
20. Opel DJ, Diekema DS, Marcuse EK. A critique of criteria for evaluating vaccines for inclusion in mandatory school immunization programs. Pediatrics. 2008; 122(2):e504-e510.
21. Cassels AK. Vaccination against human papillomavirus [letter]. CMAJ. 2007; 177(12):1526. (Pubitemid 350248170)
22. MacDonald N, Stanbrook MB, Hébert PC. Human papillomavirus vaccine risk and reality. CMAJ. 2008;179(6):503.
23. Schlesinger M. Health policy analysis and the search for hidden meaning. J Health Polit Policy Law. 2006;31(2):237-249. (Pubitemid 43727233)
24. deLeon P. Models of policy discourse: Insights versus prediction. Policy Stud J. 1998;26(1):147-161. (Pubitemid 128723374)
25. Fischer F. Reframing Public Policy: Discursive Politics and Deliberative Practices. New York, NY: Oxford University Press; 2003.
26. Fischer F, Forester J, eds. The Argumentative Turn in Policy Analysis and Planning. Durham, NC: Duke University Press; 1993.
27. Hajer MA, Wagenaar H, eds. Deliberative Policy Analysis: Understanding Governance in the Network Society. New York, NY: Cambridge University Press; 2003.
28. Schwartz-Shea P, Yanow D. "Reading" "methods" "texts": How research methods texts construct political science. Polit Res Q. 2002;55(2):457-486.
29. Stone D. Policy Paradox: The Art of Political Decision Making. Revised ed. New York, NY: W.W. Norton & Company; 2002.
30. Yanow D. How Does a Policy Mean? Interpreting Policy and Organizational Actions. Washington, DC: Georgetown University Press; 1996.
31. Sabatier PA, Jenkins-Smith HC. Policy Change and Learning: An Advocacy Coalition Approach. Boulder, CO: Westview Press; 1993.
32. Schön DA, Rein M. Frame Reflection: Toward The Resolution Of Intractable Policy Controversies. New York, NY: Basic Books; 1994.
33. Rein M, Schön DA. Reframing policy discourse. In: Fischer F, Forester J, eds. The Argumentative Turn in Policy Analysis and Planning. Durham, NC: Duke University Press; 1993.
34. National Advisory Committee on Immunization. National Advisory Committee on Immunization (NACI): Terms of Reference. Ottawa, Canada: Public Health Agency of Canada, 2009. Available at: http://www.phac-aspc.gc.ca/naci-ccni/tor-eng. php. Accessed January 7, 2009.
35. Mah CL, Guttmann A, McGeer A, Krahn M, Deber RB. Compulsory schoolentry vaccination laws and exemptions: who is opting out in Ontario and why does it matter? Healthc Policy. 2010; 5(4):37-46.
36. National Advisory Committee on SARS and Public Health. Learning from SARS: Renewal of Public Health in Canada [Naylor Report]. Ottawa, Canada: Health Canada; 2003.
37. National Immunization Strategy. National Immunization Strategy: Final Report 2003. A Report from the F/P/T Advisory Committee on Population Health and Health Security (ACPHHS) to the Conference of F/P/T Deputy Ministers of Health. Ottawa, Canada: Health Canada; 2003.
38. Department of Finance Canada. Budget Plan 2003. Ottawa, Canada: Queen's Printer; 2003.
39. Department of Finance Canada. Budget Plan 2004: New Agenda for Achievement. Ottawa, Canada: Queen's Printer; 2004.
40. Canadian Immunization Committee. Recommendations on a Human Papillomavirus Immunization Program. Ottawa, Canada: Queen's Printer; 2008.
41. Pelletier L, Chung P, Duclos P, Manga P, Scott J. A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine. 1998;16(9-10):989-996. (Pubitemid 28276013)
42. Brisson M, Edmunds WJ. The costeffectiveness of varicella vaccination in Canada. Vaccine. 2002;20(7-8):1113-1125.
43. House of Commons of Canada. Standing Committee on Finance. Pre- Budget Consultations 2006. 39th Parliament, 1st Session, October 25 (2006) (testimony of Mr. Christian Blouin, Director, Public Health Policy and Government Relations, Merck Frosst Canada Inc.)
44. House of Commons of Canada. Standing Committee on Finance. Pre- Budget Consultations 2006. 39th Parliament, 1st Session, October 25 (2006) (testimony of Dr. Diane Francoeur (President, Association of Obstetricians and Gynecologists of Quebec).
45. House of Commons of Canada. Standing Committee on Finance. Pre- Budget Consultations 2006. 39th Parliament, 1st Session, September 26, (2006) (testimony of Dr. Ian Gemmill, Co-Chair, Canadian Coalition for Immunization Awareness and Promotion).
46. House of Commons of Canada. Standing Committee on Finance. Pre- Budget Consultations 2006. 39th Parliament, 1st Session, September 19 (2006) (testimony of Dr. Gary Pekeles, Canadian Paediatric Society President Elect, as an individual).
47. House of Commons of Canada. House of Commons Debates (Hansard). Prebudget consultations. December 13 (2006) (testimony of Mr. Michael Savage, Dartmouth-Cole Harbour, Lib.).
48. Budget Implementation Act, S.C. 2007, c. 29.
49. Department of Finance Canada. Budget Plan 2007: Aspire to a Stronger, Safer, Better Canada. By Flaherty HJM. Ottawa, Canada: Queen's Printer; 2007.
50. Dubey V. Differing perspectives on the Gardasil/HPV-Vaccination program in Ontario. Panel presentation at: Public Health Ethics, Law and Policy Seminar Series Inaugural Seminar; March 20, 2008; Toronto, Ontario, Canada.
51. Finnerty K. Healthcare and the media: a healthy relationship? Panel presentation at: Health Policy, Management and Evaluation Research Day; May 7, 2008; Toronto, Canada.
52. CBC News. Ontario's HPV program expert-approved: Premier. CBC. ca. August 2, 2007. Available at: http://www. cbc.ca/canada/toronto/story/2007/08/02/ ontario-hpv.html. Accessed April 30, 2009.
53. CBC News. N.L. school girls will get HPV vaccine. CBC.ca. August 7, 2007. Available at: http://www.cbc.ca/canada/newfoundland-labrador/story/2007/08/07/ hpv-vaccine.html. Accessed April 30, 2009.
54. CBC News. Nova Scotia girls to get HPV vaccine. CBC.ca. June 20, 2007. Available at: http://www.cbc.ca/health/story/2007/06/20/hpv-ns.html. Accessed April 30, 2009.
55. Gulli C. Our girls are not guinea pigs. Macleans. August 27, 2007:38-42. Available at: http://www.macleans.ca/science/health/article.jsp?content= 20070827-108312-108312. Accessed May 12, 2011.
56. Butler-Jones D. Canada's Chief Public Health Officer refutes Maclean's article on HPV vaccine [media release]. Ottowa, Canada: Public Health Agency of Canada; August 17, 2007. Available at: http://www.phac-aspc.gc.ca/media/cpho- acsp/hpv-vaccine070817-eng.php. Accessed August 3, 2011.
57. Lippman A, Melnychuk R, Shimmin C, Boscoe M. Human papillomavirus, vaccines and women's health: Questions and cautions. CMAJ. 2007;177(5):484-487. (Pubitemid 47359772)
58. House of Commons of Canada. Standing Committee on Health. Study on Post-Market Surveillance of Pharmaceutical Products. 39th Parliament, 2nd Session, April 15 (2008) (testimony of Ms. Christiane Gagnon, Québec, BQ).
59. Hammond G. The ABCs of New Vaccine Program Development in Canada: Or, How do NACI/CIC/F/P/T Make a Difference in Our Vaccine Programs? Featuring HPV and Other Vaccines. Presentation at: 8th Canadian Immunization Conference; December 1, 2008; Toronto, Canada.
60. CBC News. Alberta to offer HPV vaccine this fall. CBC.ca. June 12, 2008. Available at: http://www.cbc.ca/canada/edmonton/story/2008/06/12/edm-hpv.html. Accessed December 10, 2008.
61. Public Health Agency of Canada. Publicly Funded Immunization Programs in Canada-Routine Schedule for Infants and Children (including special programs and catch-up programs). Ottawa, Canada: Public Health Agency of Canada, 2009. Available at: http://www.phac-aspc.gc.ca/im/ptimprogprogimpt/table-1-eng.php. Accessed October 13, 2009.
62. Alberta Conference of Catholic Bishops. A Message from the Alberta Catholic Bishops to Parents, Trustees, Superintendents of Education of Catholic School Boards and to the Catholic Educational Community, June 23, 2008. Available at: http://www.edmontoncatholic-church. com/pastoral-letters/ HPVmessage.shtml. Accessed December 10, 2008.
63. Gostin LO. Public health, ethics, and human rights: a tribute to the late Jonathan Mann. J Law Med Ethics. 2001;29(2): 121-130. (Pubitemid 33723261)
64. Hann A, Peckham S. To vaccinate or to screen-is that the question? Int J Health Plann Manage. 2008;23(1):69-78.
65. Blumberg BS. Hepatitis B. In: Artenstein AW, ed. Vaccines: A Biography. New York, NY: Springer; 2010:301-315.
66. House of Commons of Canada. 2006. House of Commons Debates (Hansard). The Budget. December 13 (2006) (testimony of Mr. Dave MacKenzie, Parliamentary Secretary to the Minister of Public Safety, CPC).
67. Ontario Ministry of Health and Long- Term Care. Ontario's Grade 8 HPV Vaccination Program. Toronto, Canada: Queen's Printer for Ontario, 2008. Available at: http://www.hpvontario.ca/index.html. Accessed April 30, 2009.
68. National Center for Immunization and Respiratory Diseases. Vaccines and Preventable Diseases: Vaccination HPV. Human Papillomavirus (HPV). Atlanta, GA: Centers for Disease Prevention and Control, 2008. Available at: http://www. cdc.gov/vaccines/vpd-vac/hpv/default.htm. Updated July 29, 2009. Accessed October 13, 2009.
69. Dawson A. Therapeutic vaccines: a solution to the prevention problem? Vaccine. 2005;23(17-18):2363-2366. (Pubitemid 40341485)
70. de Courval FP, DeSerres G, Duval B. Varicella vaccine: factors influencing uptake. Can J Public Health. 2003;94(4): 268-271. (Pubitemid 36939515)
71. Gustafson R, Skowronski DM. Disparities in varicella vaccine coverage in the absence of public funding. Vaccine. 2005;23(27):3519-3525. (Pubitemid 40602786)
72. House of Commons of Canada. Standing Committee on Health. Study on Post-Market Surveillance of Pharmaceutical Products. 39th Parliament, 2nd Session, April 15 (2008) (testimony of Dr. Robyn Tamblyn, Scientific Director, Clinical and Health Informatics Research, Department of Medicine, McGill University).
73. House of Commons of Canada. Standing Committee on Health. Study on Post-Market Surveillance of Pharmaceutical Products. 39th Parliament, 2nd Session, May 1 (2008) (testimony of Dr. Barbara Law, Interim Director, Vaccine Preventable Diseases Prevention and Vaccine Safety, Public Health Agency of Canada).
74. Picard A. How politics pushed the HPV vaccine. Globe and Mail. August 11, 2007:A.1. Available at: http://www. theglobeandmail.com/servlet/story/RTGAM. 20070811.whpv11/BNStory/specialScienceandHealth. Accessed December 10, 2008.
75. Health Canada. Canadian National Report on Immunization, 1997. J Can Paediatr Soc. 1998;3(Suppl B). Available at: http://www.phac-aspc.gc.ca/ publicat/pch/vol3supb/index-eng.php. Accessed May 12, 2011.
76. Health Canada. 3rd Canadian National Immunization Conference: Partnerships for Health Through Immunization, Plenary Session Presentation Abstracts. Ottawa, Canada: Health Canada, 1998. Available at: http://www.phac-aspc.gc.ca/cnic-ccni/1998/confpro98-eng.php. Accessed April 30, 2009.